

SAME SIZE ARTWORK  
SIZE : 88 mm X 186 mm

24 mm

SPACE FOR  
PHARMACODE

**candid**<sup>™</sup>  
Dusting Powder  
**clotrimazole**

SPACE FOR  
PHARMACODE

SPACE FOR  
PHARMACODE

**Composition**

Clotrimazole USP 1% w/w  
Purified Talc BP base q.s

**Therapeutic Class**

T0130

**Description**

A printed plastic bottle fitted with a plug and red coloured cap containing a fine white powder with a pleasant odour.

**Pharmacology (Summary of Pharmacodynamics and Pharmacokinetics)**

**Pharmacodynamics**

Clotrimazole is an imidazole antifungal agent and is effective against a wide variety of fungi including Epidermophyton, Microsporum and Trichophyton spp., Coccidioides immitis, Histoplasma capsulatum, Aspergillus and Candida spp. Other fungi responding to Clotrimazole include Cryptococcus neoformans, Malassezia furfur (Pityrosporum orbiculare), Paracoccidioides brasiliensis, Sporothrix schenckii, Pseudallescheria, Medurella and Phialophora spp. Clotrimazole also has antibacterial action and some strains of Staphylococcus aureus and Streptococcus pyogenes have been reported to be sensitive. Clotrimazole is believed to exert its activity on the cell membrane of the fungus. It appears that the drug inhibits protein synthesis and so influences the utilisation and the incorporation of the acylated amino acids essential for fungi.

**Pharmacokinetics**

Clotrimazole appears to be well absorbed in humans following oral administration and is eliminated mainly as inactive metabolites. Following topical and vaginal administration, however, Clotrimazole appears to be minimally absorbed. Six hours after the application of radioactive Clotrimazole 1% cream and 1% solution onto intact and acutely inflamed skin, the concentration of Clotrimazole varied from 100 mcg / cm<sup>3</sup> in the stratum corneum to 0.5 to 1 mcg / cm<sup>3</sup> in the stratum reticulare, and 0.1 mcg / cm<sup>3</sup> in the subcutis. No measurable amount of radioactivity (£ 0.001 mcg/ml ) was found in the serum within 48 hours after application under occlusive dressing of 0.5 ml of the solution or 0.8 g of the cream. Only 0.5% or less of the applied radioactivity was excreted in the urine.

**Indications**

- Concomitant therapy with **CANDID** Cream / Lotion or **CANDID-B** Cream / Lotion particularly in Intertriginous Dermatmycoses seen with Tinea Pedis, Tinea Cruris, Tinea Corporis, Candidal Dermatitis, Tinea Versicolor, Erythrasma, etc.
- Maintenance or follow up treatment to protect against reinfection.
- Protection against spread of infection by simultaneous application to clothing or footwear.
- Symptomatic relief and prevention of secondary fungal or bacterial infection in prickly heat.

PE00000 MY

SAME SIZE ARTWORK  
SIZE : 88 mm X 186 mm

**Contraindications**

Except for possible hypersensitivity reactions, there are no contraindications to **CANDID** Powder.

**Side Effects / Adverse Reactions**

Except for rare cases of hypersensitivity, no side-effects are reported.

**Drug Interactions**

None reported.

**Precautions / Warnings**

For irritation or sensitivity caused with the use of Clotrimazole; treatment should be discontinued and appropriate therapy instituted.

The patient should be advised to use the medication for the full treatment time even though the symptoms may have improved. This medicine should be used in the first trimester of pregnancy after consideration of the benefit/risk relation and by physician's decision. It is not known whether Clotrimazole is excreted in human being's milk. As many drugs are excreted in human being's milk, caution should be exercised with Clotrimazole used by nursing mothers.

**Pregnancy and Lactation**

This medicine should be used in the first trimester of pregnancy after consideration of the benefit/risk relation and by physician's decision. It is not known whether Clotrimazole is excreted in human being's milk. As many drugs are excreted in human being's milk, caution should be exercised with Clotrimazole used by nursing mothers.

**Recommended Dosage, Dosage Schedule and Route of Administration**

**CANDID** Powder should be dusted over the affected area several times daily as required.

**Symptoms and Treatment for Overdosage and Antidote (s)**

Acute overdose with topical application of Clotrimazole is unlikely and it is not expected to represent a life-threatening situation.

**Packing / Pack Sizes**

Bottle of 30 gm.

**Shelf Life**

4 years

**Storage Conditions, User Instructions and Pharmaceutical Precautions**

Store below 30°C. Protect from light.

MAL 19900327XZ

**Date of Revision** : 30.04.2024

Manufactured by:

  
**glenmark**

**PHARMACEUTICALS LTD.**

Plot No. E-37, 39, MIDC Area,  
Satpur, Nasik - 422 007,  
Maharashtra, India.  
™ Trade Mark

**Product Registration Holder:**

Glenmark Pharmaceuticals  
(Malaysia) Sdn Bhd (660397-W)  
D-31-02, Menara Suezcap 1,  
No. 2, Jalan Kerinchi,  
59200 Kuala Lumpur, Malaysia

PE00000 MY

ICONGRAPHICS CODE:

PANTONE SHADE



PANTONE  
BLACK  
PROCESS C

**Supersedes  
Artwork Code**

PHARMACODE: